| 摘要 |
<p num="1"><br/><br/><br/>The present invention provides novel conformationally-defined macrocyclic <br/>compounds that have been demonstrated to be selective modulators of the <br/>ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, <br/>isoforms and/or variants thereof). Methods of synthesizing the novel compounds <br/>are also described herein. These compounds are useful as antagonists or <br/>inverse agonists of the ghrelin receptor and as medicaments for treatment and <br/>prevention of a range of medical conditions including, but not limited to, <br/>metabolic and/or endocrine disorders, cardiovascular disorders, obesity and <br/>obesity-associated disorders, gastrointestinal disorders, genetic disorders, <br/>hyperproliferative disorders and inflammatory disorders.<br/>
|
